Effect of switching from linagliptin to teneligliptin dipeptidyl peptidase-4 inhibitors in older patients with type 2 diabetes mellitus

Eugene Han, Minyoung Lee, Yong Ho Lee, Hye Soon Kim, Byung Wan Lee, Bong Soo Cha, Eun Seok Kang

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


Introduction: Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely prescribed for type 2 diabetes (T2D) and their glycemic control effects are well studied. However, information regarding the effects of switching DPP-4 inhibitors is limited, especially in older patients. Research Design and Methods: We investigated whether switching from linagliptin to teneligliptin decreases blood glucose in older (≥65 years) T2D patients. In total, 164 patients with T2D who switched from linagliptin to teneligliptin for >12 weeks were included and the primary outcome was glycemic changes. Results: Switching from linagliptin to teneligliptin ameliorated fasting blood glucose (148.1 ± 47.1 to 139.6 ± 43.4 mg/dL), glycated hemoglobin (HbA1c; 7.9 ± 1.3 to 7.5 ± 1.2%), and postprandial blood glucose (224.8 ± 77.4 to 205.8 ± 70.8 mg/dL) levels (all P < 0.05). Low- density lipoprotein cholesterol concentration was reduced while liver and kidney functions were maintained. Subgroup analysis showed that glucose control improved more in patients with uncontrolled hyperglycemia (HbA1c > 8.0%) and chronic kidney disease (estimated glomerular filtration rate <90 mL/min/1.73m2). Multiple logistic analysis indicated higher baseline HbA1c was the strongest predictor of teneligliptin switching response. Conclusion: Switching from linagliptin to teneligliptin helps maintain kidney function and reduce blood glucose safely in older patients with T2D.

Original languageEnglish
Pages (from-to)4113-4121
Number of pages9
JournalDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Publication statusPublished - 2020

Bibliographical note

Funding Information:
Sponsorship for this study was funded by the Handok Inc, Seoul, Korea, and by the Severance Hospital Research Fund for Clinical excellence (SHRC, C-2020-0016). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Publisher Copyright:
© 2020, Dove Medical Press Ltd. All rights reserved.

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Pharmacology


Dive into the research topics of 'Effect of switching from linagliptin to teneligliptin dipeptidyl peptidase-4 inhibitors in older patients with type 2 diabetes mellitus'. Together they form a unique fingerprint.

Cite this